• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Schulman IRB adds Biosafety Officer Daniel Eisenman

Schulman IRB adds Biosafety Officer Daniel Eisenman

January 26, 2017
CenterWatch Staff

Schulman IRB, a central IRB in customer service and technology, announced that Daniel Eisenman, Ph.D., RBP, SM (NRCM), CBSP, has joined the organization as Biosafety Officer.

In his new role, Dr. Eisenman will work with Schulman leadership to develop and manage a forthcoming institutional biosafety committee (IBC) service. He will also provide consulting services for research organizations navigating the IBC landscape. The new IBC service represents Schulman's response to many requests from research sponsors and institutions seeking an independent option for establishing IBCs when required by federal regulations.

"We're delighted to work with someone so experienced and knowledgeable as Dr. Eisenman," said Michael Woods, president and CEO of Schulman IRB. "He has already built and managed several biosafety programs and worked with many IBCs. He has a knack for explaining complex concepts in a clear, understandable manner. All of this makes him the ideal leader for Schulman's IBC services."

Dr. Eisenman previously served as Biological Safety Officer, Alternate Responsible Official for CDC select agents, and Institutional Contact for Dual Use Research at the University of North Carolina Chapel Hill. He has served on multiple institutional biosafety committees and BSL-3 oversight committees as well as consulted for multiple IACUC committees.

Schulman's commercial IBC service will launch in the spring of 2017.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing